All lobbying filings

S-3 GROUP

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $20,000.00 income · posted Apr 17, 2026

Official filing document

Lobbying activity 3

Health Issues

Issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.

Trade (domestic/foreign)

Issues related to tariffs and importation of counterfeit drugs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.